Ascendis Pharma A/S (NASDAQ:ASND) Posts Earnings Results

Key Points

• Ascendis beat quarterly earnings expectations: EPS was $1.94 versus the $0.89 consensus, while revenue of $418.71 million topped analysts’ $409.40 million estimate.
• Product revenue grew 89% year over year to €366 million. YORVIPATH contributed €291 million, SKYTROFA €59 million and newly launched YUVIWEL €16 million.
• Operating cash flow reached €189 million in the quarter, and the company raised its 2026 expectation to at least €600 million; it ended the quarter with €964 million in cash.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) posted its quarterly earnings data on Thursday. The biotechnology company reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $1.05, FiscalAI reports. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. The business had revenue of $418.71 million for the quarter, compared to analysts' expectations of $409.40 million.

Here are the key takeaways from Ascendis Pharma A/S's conference call:

• Q3 product revenue rose 89% year over year to €366 million, including €291 million from YORVIPATH, €59 million from SKYTROFA and €16 million from newly launched YUVIWEL.
• YORVIPATH continued to grow, with U.S. demand described as steady and revenue increasing €39 million sequentially; the company said it expects further growth as it expands commercial availability, including 15 additional markets anticipated in 2027.
• YUVIWEL had about 340 U.S. patients enrolled through October, with more than 80% approved for reimbursement. Ascendis expects a European Commission decision before year-end and, if approved, plans a Germany launch in early 2027.
• Operating cash flow was €189 million in Q3, and Ascendis raised its 2026 expectation to at least €600 million; it ended the quarter with €964 million in cash. Management reiterated its longer-term revenue goals of more than €5 billion in 2030 and €10 billion in 2035, which depend on continued product growth, geographic expansion and pipeline development.
• The company is advancing label-expansion and combination-therapy programs, including a Phase III achondroplasia combination trial that has begun recruiting. Ascendis said the trial was redesigned after regulatory feedback to include a growth-hormone monotherapy arm, which enlarged the study and delayed it by a few months.

Ascendis Pharma A/S Trading Up 2.6%

Shares of NASDAQ:ASND traded up $6.80 during trading on Thursday, reaching $266.08. 718,268 shares of the stock were exchanged, compared to its average volume of 700,453. The firm's 50-day moving average price is $242.59 and its 200 day moving average price is $239.48. The firm has a market cap of $16.60 billion, a price-to-earnings ratio of 20.67 and a beta of 0.40. Ascendis Pharma A/S has a 12-month low of $188.07 and a 12-month high of $282.15. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99.

Analyst Upgrades and Downgrades

ASND has been the topic of several recent analyst reports. Canaccord Genuity Group set a $268.00 target price on Ascendis Pharma A/S in a research report on Monday, October 26th. BMO Capital Markets reissued an "outperform" rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Citigroup lowered their price target on Ascendis Pharma A/S from $360.00 to $330.00 and set a "buy" rating for the company in a report on Monday, October 26th. Morgan Stanley dropped their price objective on shares of Ascendis Pharma A/S from $275.00 to $273.00 and set an "overweight" rating for the company in a research note on Tuesday, September 1st. Finally, TD Cowen reaffirmed a "buy" rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Nineteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $305.95.

Insider Activity at Ascendis Pharma A/S

In related news, SVP Mads Bodenhoff sold 3,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the transaction, the senior vice president owned 3,000 shares in the company, valued at approximately $810,570. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jean-Jacques Bienaimé purchased 2,000 shares of Ascendis Pharma A/S stock in a transaction on Friday, August 14th. The shares were acquired at an average cost of $246.33 per share, for a total transaction of $492,660.00. Following the completion of the transaction, the director owned 2,900 shares of the company's stock, valued at $714,357. This represents a 222.22% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 40.00% of the company's stock.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.